Design: Meta-analysis of randomised trials
Population: 16 trials, 2,325 adults undergoing flexible bronchoscopy
Primary outcome: Respiratory depression, hypotension and bradycardia
Effect: Respiratory depression RR 0.51 (0.36–0.73); hypotension RR 0.50 (0.34–0.73)

This meta-analysis pooled 16 randomised trials with 2,325 adults undergoing flexible bronchoscopy, comparing remimazolam — an ultra-short-acting benzodiazepine broken down by tissue esterases — with dexmedetomidine, midazolam or propofol.

Remimazolam was associated with less respiratory depression (RR 0.51, 95% CI 0.36–0.73), hypotension (RR 0.50) and bradycardia (RR 0.37). Onset was faster than with dexmedetomidine but slightly slower than propofol. Procedure success was similar. Recovery was quicker than with dexmedetomidine or midazolam, by a few minutes.

Comparators were pooled together, and trial quality and sedation protocols varied. The time savings are small; the safety advantage on breathing and blood pressure is the clinically relevant part, especially in patients with limited respiratory reserve.

Consider remimazolam, where available, for bronchoscopy sedation in patients with limited respiratory reserve or haemodynamic instability.
Flumazenil reverses remimazolam, as with other benzodiazepines.
Continuous oximetry and capnography where possible remain essential whatever the sedative.
Procedure success did not differ, so the choice turns on safety and recovery.

Why it matters

Sedation-related hypoxia and hypotension are the main procedural risks in bronchoscopy, and this agent roughly halved both.

The statistics, in plain English

A relative risk of 0.51 means about half the rate of respiratory depression compared with other sedatives combined. Pooling different comparators means the size of the advantage over any one drug is less certain.